A Systematic Review and Meta-Analysis of Randomized Control Trials to Check Role of Non-Steroidal Anti-inflammatory Drugs as Protective Factor in Alzheimer Disease Subjects
Background: Alzheimer’s disease is the major neurodegenerative disease, affecting more than two third cases of dementia in the world. NSAIDs are widely used anti-inflammatory analgesic agents representing 7.7% of worldwide prescriptions of which 90% are in patients over 65 years old. Based on mixed findings observed by different RCTs, a systematic review and meta-analysis were conducted to develop a better understanding of the protective role of Non-steroidal anti-inflammatory drugs (NSAIDs) in AD. Methods: Database search was Pubmed, WebScience, and Embase. RCTs investigating the effect of NSAIDs on AD or test scores assessing cognitive function in people without AD at baseline were included. Three indicators were MMSE Score, ADAS-cog score, and CDR-sob. 10 studies were included in the present Meta-analysis. Results: For the ADAS-cog score, the pooled effect size was -0.31 with 95% CI -0.06 to 0.02, which was statistically significant (p = 0.03). MMSE score difference, the pooled effect size was -0.06 with 95% CI -0.22 to 0.10, which was statistically insignificant (p-value = 0.47). For the MMSE average score, the pooled effect size was -0.002 with 95% CI -0.03 to 0.07, which was statistically insignificant (p-value = 0.87). For the CDR-sob score difference, the pooled effect size calculated using the random effect model was -0.06 with 95% CI -0.39 to 0.05 which was statistically insignificant (p = 0.14). For CDR-sob average score, the pooled effect size calculated using the random effect model was 0.21 with 95% CI -0.09 to 0.51, which was statistically insignificant (p-value = 0.17). Conclusion: Present Meta-analysis shows that NSAIDs in general are not effective in the treatment of AD. They also have no protective effect against the development of AD on their sustained use.
References
[1]
Aisen, P.S., Schmeidler, J. and Pasinetti, G.M. (2002) Randomized Pilot Study of Nimesulide Treatment in Alzheimer’s Disease. Neurology, 58, 1050-1054. https://doi.org/10.1212/WNL.58.7.1050
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W. and Ferri, C.P. (2013) The Global Prevalence of Dementia: A Systematic Review and Metaanalysis. Alzheimer’s Association, 9, 63-75.e2. https://doi.org/10.1016/j.jalz.2012.11.007
[4]
Prince, M.J., Wimo, A., Guerchet, M.M., Ali, G.C., Wu, Y.T. and Prina, M. (2015) World Alzheimer Report 2015—The Global Impact of Dementia. An Analysis of Prevalence, Incidence, Cost and Trends. Alzheimer’s Disease International, London.
[5]
Wu, Y.T., Beiser, A.S., Breteler, M.M.B., Langa, K.M., et al. (2017) The Changing Prevalence and Incidence of Dementia over Time—Current Evidence. Nature Reviews Neurology, 13, 327-339. https://doi.org/10.1038/nrneurol.2017.63
[6]
Miguel-álvarez, M., et al. (2015) Non-Steroidal Anti-Inflammatory Drugs as a Treatment for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Treatment Effect. Drugs Aging, 32, 139-147. https://doi.org/10.1007/s40266-015-0239-z
[7]
Talwar, P., et al. (2016) Dissecting Complex and Multifactorial Nature of Alzheimer’s Disease Pathogenesis: A Clinical, Genomic, and Systems Biology Perspective. Molecular Neurobiology, 53, 4833-4864. https://doi.org/10.1007/s12035-015-9390-0
[8]
Reines, S.A., Block, G.A., Morris, J.C., Liu, G., Nessly, M.L., Lines, C.R., Norman, B.A. and Baranak, C.C. (2004) Rofecoxib: No Effect on Alzheimer’s Disease in a 1-Year, Randomized, Blinded, Controlled Study. Neurology, 62, 66-71. https://doi.org/10.1212/WNL.62.1.66
[9]
Thal, L.J., et al. (2005) A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment. Neuropsychopharmacology, 30, 1204-1215. https://doi.org/10.1038/sj.npp.1300690
[10]
Williams, C.S., Mann, M. and DuBois, R.N. (1999) The Role of Cyclooxygenases in Inflammation, Cancer, and Development. Oncogene, 18, 7908-7916.
[11]
Cagnin, A., Brooks, D.J., Myers, R., et al. (2001) In-Vivo Measurement of Activated Microglia in Dementia. The Lancet, 358, 461-467. https://doi.org/10.1016/S0140-6736(01)05625-2
[12]
Veronese, N., et al. (2017) Low-Dose Aspirin Use and Cognitive Function in Older Age: A Systematic Review and Meta-analysis. Journal of the American Geriatrics Society, 65, 1763-1768. https://doi.org/10.1111/jgs.14883
[13]
Scarpini, E., Scheltens, P. and Feldman, H. (2003) Treatment of Alzheimer’s Disease; Current Status and New Perspectives. The Lancet Neurolgy, 2, 539-547. https://doi.org/10.1016/S1474-4422(03)00502-7
[14]
Etminan, M., Gill, S. and Samii, A. (2003) Effect of Non-Steroidal Anti-Inflammatory Drugs on Risk of Alzheimer’s Disease: Systematic Review and Meta-Analysis of Observational Studies. BMJ, 327, Article 128. https://doi.org/10.1136/bmj.327.7407.128
[15]
Zhou, Y., Boudreau, D.M. and Freedman, A.N. (2014) Trends in the Use of Aspirin and Nonsteroidal Anti-Inflammatory Drugs in the General U.S. Population. Pharmacoepidemiology and Drug Safety, 23, 43-50. https://doi.org/10.1002/pds.3463
[16]
Aisen, P.S., et al. (2003) Effects of Rofecoxib or Naproxen Vs Placebo on Alzheimer Disease Progression: A Randomized Controlled Trial. JAMA, 289, 2819-2826. https://doi.org/10.1001/jama.289.21.2819
[17]
McGeer, P.L., Schulzer, M. and McGeer, E.G. (1996) Arthritis and anti-Inflammatory Agents as Possible Protective Factors for Alzheimer’s Disease: A Review of 17 Epidemiologic Studies. Neurology, 47, 425-432. https://doi.org/10.1212/WNL.47.2.425
[18]
Stewart, W.F., Kawas, C., Corrada, M. and Metter, E.J. (1997) Risk of Alzheimer’s Disease and Duration of NSAID Use. Neurology, 48, 626-632. https://doi.org/10.1212/WNL.48.3.626
[19]
Hamrick, I., Hafiz, R. and Cummings, D.M., (2013) Use of Days of the Week in a Modified Mini-Mental State Exam (M-MMSE) for Detecting Geriatric Cognitive Impairment. JABFM, 26, 429-435. https://doi.org/10.3122/jabfm.2013.04.120300
[20]
Kolibas, E., Korinkova, V., Novotny, V., Vajdickova, K. and Hunakova, D. (2000) ADAS-Cog (Alzheimer’s Disease Assessment Scale-Cognitive Subscale)—Validation of the Slovak Version. Bratislavske Lekarske Listy, 101, 598-602.
[21]
O’Bryant, S.E., Waring, S.C., DVM, Cullum, M., et al. (2008) Staging Dementia Using Clinical Dementia Rating Scale Sum of Boxes Scores. Archives of Neurology, 65, 1091-1095. https://doi.org/10.1001/archneur.65.8.1091
[22]
Borenstein, M., Hedges, L.V., Higgins, J.P.T. and Rothstein, H.R. (2009) Introduction to Meta-Analysis. John Wiley & Sons, Ltd., Hoboken. https://onlinelibrary.wiley.com/doi/book/10.1002/9780470743386
[23]
Wilcock, G.K., et al. (2008) Efficacy and Safety of Tarenflurbil in Mild to Moderate Alzheimer’s Disease: A Randomised Phase II Trial. The Lancet Neurology, 7, 483-493. https://doi.org/10.1016/S1474-4422(08)70090-5
[24]
Leoutsakos, J.M.S., Muthen, B.O., Breitner, J.C.S., Lyketsos, C.G. and ADAPT Research Team (2012) Effects of Non-Steroidal Anti-Inflammatory Drug Treatments on Cognitive Decline Vary by Phase of Pre-Clinical Alzheimer Disease: Findings from the Randomized Controlled Alzheimer’s Disease Anti-Inflammatory Prevention Trial. International Journal of Geriatric Psychiatry, 27, 364-374. https://doi.org/10.1002/gps.2723
[25]
Pasqualetti, P., et al. (2009) A Randomized Controlled Study on Effects of Ibuprofen on Cognitive Progression of Alzheimer’s Disease. Aging Clinical and Experimental Research, 21, 102-110. https://doi.org/10.1007/BF03325217
[26]
Green, R.C., et al. (2009) Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients with Mild Alzheimer Disease: A Randomized Controlled Trial. JAMA, 302, 2557-2564. https://doi.org/10.1001/jama.2009.1866
[27]
de Jong, D., et al. (2008) No Effect of One-Year Treatment with Indomethacin on Alzheimer’s Disease Progression: A Randomized Controlled Trial. PLOS ONE, 3, e1475. https://doi.org/10.1371/journal.pone.0001475
[28]
Ryan, J., et al. (2020) Randomized Placebo-Controlled Trial of the Effects of Aspirin on Dementia and Cognitive Decline. Neurology, 95, e320-e331. https://doi.org/10.1212/WNL.0000000000009277
[29]
Babiloni, C., et al. (2009) Ibuprofen Treatment Modifies Cortical Sources of EEG Rhythms in Mild Alzheimer’s Disease. Clinical Neurophysiology, 120, 709-718. https://doi.org/10.1016/j.clinph.2009.02.005
[30]
Szekely, C.A., et al. (2008) NSAID Use and Dementia Risk in the Cardiovascular Health Study: Role of APOE and NSAID Type. Neurology, 70, 17-24. https://doi.org/10.1212/01.wnl.0000284596.95156.48
[31]
Hayden, K.M., et al. (2007) Does NSAID Use Modify Cognitive Trajectories in the Elderly? The Cache County study. Neurology, 69, 275-282. https://doi.org/10.1212/01.wnl.0000265223.25679.2a
[32]
ADAPT Research Group et al. (2007) Naproxen and Celecoxib Do Not Prevent AD in Early Results from a Randomized Controlled Trial. Neurology, 68, 1800-1808. https://doi.org/10.1212/01.wnl.0000260269.93245.d2
[33]
In’t Veld, B.A., et al. (2001) Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer’s Disease. The New England Journal of Medicine, 345, 1515-1521. https://doi.org/10.1056/NEJMoa010178
[34]
Szekely, C.A., Zandi, P.P., Ek, M., Breitner, J.C.S., Goodman S.N., Thorne, J.E. and Messias, E. (2004) Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer’s Disease: A Systematic Review. Neuroepidemiology, 23, 159-169. https://doi.org/10.1159/000078501
